Clinical Risk Scores in Prediction Outcome of Acute UGIT Bleeding in Non Cirrhotic Patients
Launched by ASSIUT UNIVERSITY · Feb 4, 2024
Trial Information
Current as of August 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to compare four different scoring systems that help predict the outcomes for patients experiencing upper gastrointestinal (GI) bleeding. These scoring systems will help doctors determine if a patient will need further treatment, if there is a chance of bleeding again, how likely they are to survive the next thirty days, and how long they might need to stay in the hospital.
To participate in this study, you must be an adult over 18 years old who is not suffering from liver cirrhosis (a severe liver condition). You should have symptoms like vomiting blood, passing dark stools, or having blood found in your stomach through a tube in the emergency room. The trial is not yet recruiting, so it hasn’t started accepting participants yet. If you qualify and choose to take part, you’ll help researchers better understand how to manage upper GI bleeding, which can ultimately improve care for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult non cirrhotic patients
- • patients more than 18 years old
- • Hematemesis or coffee grounds vomiting.
- • Melena with or without hematemesis.
- • Blood in nasogastric tube in emergency unit.
- Exclusion Criteria:
- • Patients younger than 18 years old.
- • Patients known to be cirrhotic.
- • Patients presented with GIT bleeding but refuse to be examined by GIT endoscopy.
About Assiut University
Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported